Skip to Content

Eduardo Vilar-Sanchez, MD, PhD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Affiliate Faculty, Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, Human and Molecular Genetics and Biostatistics, Bioinformatics and Systems Biology Graduate Programs, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

  1. Molecular biology of premalignant intestinal polyps and intestinal carinogenesis.
  2. Molecular classification of colorectal cancer.
  3. Mouse models of colorecta cancer and cross-species comparisons.
  4. Hereditary Colorectal Cancer Syndromes, Lynch Syndrome and Familial Adenomatous Polyposis.
  5. Chemoprevention Drug Development.
  6. Targeted Therapies in Chemoprevention.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler St
Unit Number: 1360
Houston, TX 77030
Room Number: CPB6.3526

Education & Training

Degree-Granting Education

2009 University Miguel Hernandez, Alicante, Spain, PHD, Cum Laude, Honors, Molecular Biology
2007 Spanish National Cancer Center (CNIO), Madrid, Spain, MS, Molecular Oncology
2002 University Miguel Hernandez Medical School, Alicante, Spain, MD, Medicine

Postgraduate Training

12/2009-12/2011 Clinical Fellowship, Hematology/Oncology, University of Michigan, Ann Arbor, MI, Francis P. Worden, MD
7/2007-11/2009 Research Fellowship, Molecular Medicine & Genetics, University of Michigan, Ann Arbor, MI, Stephen B. Gruber, MD, PhD, MPH
6/2004-6/2007 Clinical Residency, Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain, Javier Cortes, MD, PhD
6/2003-6/2004 Clinical Internship, Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain, Javier Cortes, MD, PhD

Honors and Awards

2011-2012 Young Investigator Award, American Society of Clinical Oncology
2011 Extraordinary Award for PhD dissertations, Miguel Hernandez University, Alicante, Spain
2010 Excellence in Research Award, Hematology/Oncology Fellowship Program, University of Michigan
2009 Merit Award, American Society of Clinical Oncology
2009 Outstanding Research Award, Internal Medicine Research Symposium, University of Michigan
2008 Merit Award, American Society of Clinical Oncology
2007-2009 'la Caixa' Fellowship, 'la Caixa' Foundation, Barcelona, Spain
2002 Academic Grant for Undergraduate Students, Department of Anatomy & Histology, Miguel Hernandez University, Alicante, Spain

Selected Publications

Peer-Reviewed Original Research Articles

1. Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest New Drugs 30(1):299-305, 2/2012. e-Pub 9/2010. PMID: 20820909.
2. Vilar E, Tabernero J, Gruber SB. Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res 17(23):7207-9, 2011, 12/2011. e-Pub 10/2011. PMCID: PMCPMC3422018.
3. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71(7):2632-42, 2011, 4/2011. e-Pub 2/2011. PMCID: PMCPMC3407272.
4. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10(3):395-403, 2011, 3/2011. e-Pub 1/2011. PMCID: PMCPMC3413411.
5. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794-803, 2010, 9/2010. e-Pub 2/2010. PMID: 20139156.
6. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153-62, 2010, 3/2010. e-Pub 2/2010. PMCID: PMCPMC3427139.
7. Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 15(8):2829-39, 2009, 4/2009. e-Pub 4/2009. PMCID: PMCPMC3425357.
8. Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 99(10):1607-12, 2008, 11/2008. e-Pub 10/2008. PMCID: PMC2584960.
9. Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. New drug development in digestive neuroendocrine tumors. Ann Oncol 18(8):1307-13, 8/2007. e-Pub 2/2007. PMID: 17301070.
10. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14(2):221-32, 2007, 6/2007. PMID: 17639039.

Grant & Contract Support

Title: Discovering New Prevention Strategies for Lynch Syndrome
Funding Source: Feinberg Family Gift
Role: Principal Investigator
Duration: 12/1/2013 - 12/1/2017
Title: Discovering new Targets for Chemoprevention in Familial Adenomatous Polyposis
Funding Source: Duncan Family Institute
Role: Principal Investigator
Duration: 8/1/2013 - 7/31/2015
Title: Research Initiation Funds
Funding Source: U.T. - M.D. Anderson Cancer Center
Role: Principal Investigator
Duration: 1/1/2012 - 8/1/2016
Title: Developing Targeted Therapies for Microsatellite Instable Colorectal Cancers
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 1/1/2012 - 12/30/2012
Title: Discovering new drugs to target Microsatellite Instable Colorectal Cancer using connections between gene expression profiles
Funding Source: Michigan Institute for Clinical and Health Research (MICHR) CTSA Pilot and Collaborative Grant Program
Role: Co-Investigator
Principal Investigator: Gruber
Duration: 2008 - 2009

Last updated: 3/11/2014